The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have quickly become some of the most ubiquitous drugs in the United States. Though they were originally indicated to treat diabetes, and to assist ...